Tumor Gene Mutation Testing Laboratory: Key Points for Quality Control and Compliance Management

Laboratory System Development and Compliance Fundamentals

Tumor gene mutation testing involves multiple steps, including nucleic acid extraction, amplification or sequencing, bioinformatics analysis, and report issuance. Establishing a quality management system that covers the entire workflow is critical. Laboratories may refer to the Management Measures for Clinical Gene Amplification Testing Laboratories in Medical Institutions and general requirements such as ISO 15189, and develop standard operating procedures based on their own methodological characteristics.

Performance Verification and Limit of Detection Confirmation

Before launching a new project, laboratories should conduct methodological performance verification, including common indicators such as accuracy, repeatability, analytical sensitivity, analytical specificity, and reportable range. Verification samples may include known mutant cell lines, residual clinical samples, or quality control materials. Verification results must be documented as the basis for quality judgment in subsequent routine testing.

Internal Quality Control and External Quality Assessment

Daily testing should include negative controls, positive controls, and blank controls to monitor nucleic acid contamination and amplification failure. Regular participation in external quality assessment or proficiency testing helps identify systematic bias. For complex workflows such as NGS, parameters including sequencing data volume, average coverage depth, and uniformity of target region coverage should also be monitored, but specific thresholds should be set independently based on methodology and intended use.

Personnel Competence and Document Management

Personnel engaged in tumor gene mutation testing should receive training in molecular diagnostics and be familiar with experimental procedures, instrument maintenance, and bioinformatics workflows. Report-issuing personnel must possess appropriate qualifications and experience to carefully interpret variant results. Document management should cover reagent acceptance, instrument calibration, software version updates, and exception handling records to ensure traceability of testing.

Bioinformatics Analysis and Data Security

The large volume of raw data generated by high-throughput sequencing requires standardized bioinformatics analysis workflows, including sequence alignment, variant calling, annotation, and filtering. Version verification should be performed when workflows are updated to avoid result drift caused by changes in software parameters. At the same time, patient genomic data privacy protection should be strengthened, with access permissions and de-identification management implemented.

Compliant Promotion and Industry Self-Regulation

In communications directed at medical professionals and the public, absolute terms such as "highest accuracy" and "absolutely reliable" should be avoided, and specific clinical outcomes should not be promised. Introductions of products and services should focus on methodological characteristics, applicable scenarios, and quality assurance measures, comply with regulatory requirements for medical devices and in vitro diagnostic reagents, and safeguard the credibility of the industry.

Continuous Improvement and Risk Management

Laboratories should regularly review quality indicators, customer feedback, and adverse events, identify weak links in workflows, and take corrective actions. Risk monitoring mechanisms should be established for key equipment, reagents, and software that affect test results to ensure service continuity and stability.